Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Using synthetic
hepatitis B
virus (HBV) mRNAs, we have shown that expression of HBV core-antigen gene sequences in Xenopus oocytes leads to the stable accumulation of 21-kDa cytoplasmic core protein (P21). In contrast, expression of precore plus core sequences leads mainly to the secretion of a heterogeneous population of proteins ranging in size from 15 to 22 kDa that collectively display viral e antigen (HBeAg) activity. We demonstrate that the precore region contains a cleavable 19 amino acid signal peptide that targets the precore proteins to the secretory pathway. The initial product of translocation (P22) is further processed during migration through the secretory pathway, apparently by a series of cleavage events at the arginine-rich carboxyl terminus, to yield multiple proteins of 15-18 kDa (
P15
-P18) that are secreted along with some P22. Our results indicate that serum HBeAg is generated by a signal peptide-mediated secretion event dependent on precore sequences.
...
PMID:A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. 318 31
Hepatitis B
e antigen (HBeAg) constitutes the nucleocapsid of
hepatitis B
virus (HBV) and occurs in association with plasma proteins, particularly with IgG, in the serum of persons infected with the virus. A polypeptide with an approximate m.w. of 15,500 (
P15
.5) is obtained either from HBeAg in the serum or from the nucleocapsid of HBV.
P15
.5 preparations from serum and virus resembled closely each other in the amino acid composition. The C-terminus amino acid sequence of
P15
.5 from serum was determined to be -Thr-Thr-Val-Val, whereas that from the virus ended with -Thr-Thr. The same sequence of four amino acid residues was found on the gene coding for the nucleopeptide of
hepatitis B
virus with a molecular size of 19,000 daltons (P19).
P15
.5 identified on the nucleotide sequence of P19 was composed of 149 amino acid residues with a calculated molecular size of 16,770 daltons. The gene coding for P19 had two -Asp-Pro-connections. By splitting these connections in P19 and
P15
.5 preparations with formic acid, smaller polypeptides were obtained with sizes predicted from the nucleotide sequence and with the N-terminus amino acid of proline as expected. One of two monoclonal antibodies raised against the core of Dane particles (HBcAg) bound with
P15
.5 preparations purified from serum and HBV. The IgG fraction from a human serum containing antibodies to HBcAg but not to HBeAg bound with
P15
.5 also. On the basis of the results obtained, the IgG molecules associated with
P15
.5 in the serum of persons infected with HBV may well represent the antibodies against HBcAg with limited specificities.
...
PMID:Immunochemical structure of hepatitis B e antigen in the serum. 618 3
Hepatitis B
e antigen (HBeAg) occurs in the serum of individuals infected with
hepatitis B
virus both free and in association with IgG. Utilizing a succession of steps involving salt precipitation, affinity chromatography, ion-exchange chromatography and isoelectrofocusing, we isolated free and IgG-bound forms of HBeAg from the sera of infected individuals with an overall gain in specific activity of 3000-fold and 540-fold, respectively. Polypeptide profiles of purified HBeAg preparations were studied by SDS-polyacrylamide gel electrophoresis in the presence of 2-mercaptoethanol. Both free and IgG-bound preparations revealed polypeptides with mol. wt. of 15500 (
P15
.5) and 16 500 (P16.5), and HBeAg activity was detected corresponding to their positions. The HBeAg polypeptides (
P15
.5/16.5) derived from sera were physicochemically different from the two polypeptides with HBeAg activity (P19 and P45) liberated from Dane particle cores by the conventional method involving incubation with Nonidet P40 and 2-mercaptoethanol. However, when core particles were prepared in the presence of a proteolytic enzyme, in addition to Nonidet P40 and 2-mercaptoethanol, they gave rise to HBeAg polypeptides with mol. wt. of 31000 (P31) and 15 500. Furthermore, P31 split into
P15
.5 when heated at 100 degrees C for 2 min. On the basis of these results,
P15
.5 may be assumed to be the essential polypeptide bearing HBeAg activity in the serum and also in Dane particles.
...
PMID:Hepatitis B e antigen polypeptides isolated from sera of individuals infected with hepatitis B virus: comparison with HBeAg polypeptide derived from Dane particles. 744 Dec 14
The HLA DR13 allele has been associated with a self-limited course of
hepatitis B
virus infection, possibly through the induction of a more vigorous
hepatitis B
core antigen (HBcAg) and/or
hepatitis B
e antigen-specific CD4(+) T cell response. HBcAg-specific CD4(+) T cell responses were investigated in three HLA DR13-positive subjects with self-limited, acute hepatitis B. HBcAg-specific, short-term T cell lines derived from these three subjects showed a dominant recognition of HBcAg peptides spanning aa 1-20 (P1), 11-30 (P2), 41-60 (P5), 111-131 (P12) and 141-160 (
P15
). In order to characterize these epitopes in more detail, CD4(+) T cell clones and cell lines were generated using HBcAg. Surprisingly, 11 of 12 T cell clones examined recognized
P15
; one recognized P10 (aa 91-111). Of four T cell lines, two recognized
P15
and two recognized P5. By peptide mapping, the minimal epitope of
P15
was located to residues (147)TVVRRRGRSP(156).
...
PMID:Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. 1246 79